

Wanbury Limited Unaudited Financial Results For The Quarter Ended 30th June, 2010

(Rs in Lacs)

		(Rs in Lacs)		
Sr. No.	Particulars	For the Qtr ended 30.06.2010	For the Qtr ended 30.06.2009	For the year ended 31.03.2010
		(Unaudited)	(Unaudited)	(Audited)
1)	Net Sales/Income from Operations	8,794.51	8,373.73	35,110.82
''	Foreign Exchange Gain (Net)	101.94	37.90	1,508.66
	Other Operating Income	158.47	138.80	967.99
	Total Income	9,054.92	8,550.43	37,587.47
	Total Indone	7,001.72	0,000.10	07,007.17
2)	Expenditure			
2,	a. (Increase)/Decrease in Stocks of			
	WIP & Finished/Traded Goods	(161.50)	87.56	(15.01)
	b. Cost of Materials	3,004.95	2,037.66	9,604.67
	c. Purchase of Traded Goods	1,159.39	1,285.90	5,089.74
	d. Staff Cost	1,302.80	1,153.68	5,159.17
	e. Depreciation/Amortisation	219.88	232.68	857.94
	f. Other Expenditure	2,439.93	2,170.39	11,399.53
	Total Expenditure	7,965.45	6,967.87	32,096.04
3)	Profit from Operations before Other Income, Interest &	1,089.47	1,582.56	5,491.43
٥,	Exceptional Items (1-2)	1,007.17	1,002.00	0,171.10
4)	Other Income	-	-	-
5)	Profit before Interest & Exceptional Items	1,089.47	1,582.56	5,491.43
6)	Interest (Net)	514.40	615.20	2,337.20
7)	Profit after Interest but before Exceptional Items	575.07	967.36	3,154.22
8)	Exceptional Items	-	-	-
9)	Profit / (Loss) from Ordinary Activities before Tax	575.07	967.36	3,154.22
10)	Tax Expense	0.26	19.44	162.08
11)	Net Profit /(Loss) from Ordinary Activities after Tax	574.81	947.92	2,992.14
12)	Extraordinary Item (Net of Tax Expense)	-	-	-
13)	Net Profit /(Loss) for the Period	574.81	947.92	2,992.14
14)	Paid - up Equity Share Capital (Face value of Rs.10/- each)	1,468.93	1,468.93	1,468.93
15)	December 9 Cumplus (evaluation December)			11 500 14
15)	Reserves & Surplus (excluding Revaluation Reserve)	2.01	/ 45	11,598.14
16)	EPS (Rs.) - Basic & Diluted before and after extraordinary items (not annualised)	3.91	6.45	20.37
17)	Public Shareholding:-			
17)	- Number of shares	8,575,010	8,520,460	8,575,010
	- Percentage of shareholding	58.38%	58.00%	58.38%
18)	Promoters and Promoter Group Shareholding:-	30.3070	30.0070	30.3070
,	a) Pledged / Encumbered			
	- Number of shares	788,500	970,000	703,500
	- Percentage of shares (as a % of the total shareholding of	12.90%	15.72%	11.51%
	promoter and promoter group)	12.7070	13.7270	11.5170
	- Percentage of shares (as a % of the total share capital of the	5.37%	6.60%	4.79%
	company)			
	b) Non - Encumbered			
	- Number of shares	5,325,776	5,198,826	5,410,776
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	87.10%	84.28%	88.49%
	- Percentage of shares (as a % of the total share capital of the company)	36.25%	35.40%	36.83%

Notes :-

- The above financial results have been reviewed by the Audit Committee and have been taken on record at the meeting of the Board of Directors of the Company held on 12th August, 2010.
- 2) The Company has only one segment of activity namely "Pharmaceuticals".
- 3) The market price of the equity shares of the Company being less than the exercise price in respect of various outstanding options to subscribe to equity shares, the aforesaid options are considered to be anti-dilutive.
- 4) Erstwhile The Pharmaceutical Products of India Limited (PPIL) merged with the Company pursuant to the Scheme of Revival cum Merger (the Scheme) approved vide order dated 24th April, 2007 by the Board for Industrial and Financial Reconstruction(BIFR) u/s 18 and other applicable provisions of the Sick Industrial Companies (Special Provisions) Act, 1985(SICA) w.e.f. 1st April, 2006, being the appointed date.

Subsequently in response to a suit filed by one of the unsecured creditors of erstwhile PPIL, challenging the Scheme, the Hon'ble Supreme Court vide its order dated 16th May, 2008, has set aside the above referred BIFR order and remitted the matter back to BIFR for considering afresh as per the provisions of SICA.

The matter is now under consideration of the BIFR. In the meanwhile, the Company has sought legal opinion and has been advised to maintain status quo ante with respect to the merger under the said Scheme and that it should take further steps only on the basis of the fresh BIFR order.

In view of the above, the Company has maintained a status quo. However, all actions taken by the Company pursuant to the sanctioned scheme shall remain subject to and without prejudice to the orders that may be passed by the BIFR while considering the case afresh pursuant to the directions of the Hon'ble Supreme Court in its order dated 16th May, 2008.

- 5) As on 30th June, 2010, the balance liability on account of oustanding euro denomineted FCCB issued by the Company has been restated at an exchange rate of Rs 56.94 and amounts to Rs 5,397.91 Lacs. The FCCB issue terms stipulate conversion of the Bonds at the pre determined exchange rate of Rs 57.22 at which rate the liability amounts to Rs 5424.45 Lacs.
- 6) Pro rata premium on outstanding FCCB amounting to Rs 105.45 Lacs and exchange gain of Rs 65.79 Lacs have been charged to the Securities Premium Account for the guarter ended 30th June, 2010.
- 7) The Company has equity investments of Rs. 3,907.71Lacs in two wholly owned subsidiaries and other company and amount recoverable of Rs.12,713.73 Lacs from them and step down subsidiary. The Company's involvement in the aforesaid entities being of strategic importance and for long term, no provision is considered necessary at this stage in respect of its investments and amounts recoverable as stated above.
 - This is matter of reference in the Limited Review report of the Statutory Auditor for the quarter ended 30.06.2010 and the Statutory Audit report for the year ended 31.03.2010
- During the Quarter, the Company had received and resolved 10 complaints. There was no investor complaint pending at the beginning and at the end of the quarter.
- 8) The figures for the previous periods have been regrouped, wherever necessary, to corrospond with the figures of the current period.

Place : Mumbai K. Chandran
Date: 12th August, 2010 Vice Chairman